Interviews

According to Bradley J. Monk, MD, FACOG, FACS, cemiplimab achieved better response and a longer overall survival compared with chemotherapy in patients with cervical cancer.

Lee Schwartzberg, MD, discusses the results of the KEYNOTE-522 trial of pembrolizumab in patients with early triple-negative breast cancer.

Dennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.

Jeffrey Zonder, MD, discusses the safety results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.

Ghassan K. Abou-Alfa, MD, discusses the use of tislelizumab as treatment of patients with unresectable hepatocellular carcinoma, as investigated in a phase 2 clinical trial.

National Cancer Institute expert, Christopher J. Melani, MD, discusses the synergy of 5 drugs that make up a targeted therapy regimen for patients with mantle cell lymphoma.

Alice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.

Leora Horn, MD, discusses the importance of the Impower133 trial.

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

Krzysztof J. Misiukiewicz, MD, discusses sequencing of treatments in patients with NTRK-positive thyroid cancer.

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Rebecca C. Arend, MD, discusses the key unmet needs in the treatment landscape for platinum-resistant ovarian cancer.

Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.

Clayton Lau, MD, advises primary care physicians and specialists on how to help address the rising prevalence of advanced-stage genitourinary cancers.

Andreana Holowatyj, PhD, MSCI, discusses the characteristics of appendiceal cancer and what differentiates it from colorectal cancer.

Toni Choueiri, MD, explains what led to the phase 3 COSMIC-313 clinical trial.

Chukwuemeka Ihemelandu, MD, explains the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.

Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.

Matthew Galsky, MD, discusses the future of bladder cancer research and the impact of new treatments such as immune checkpoint inhibitors and antibody-drug conjugates.

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Bhavana Pothuri, MD, discusses the importance of determining biomarkers of patients with endometrial cancer to decide on treatment options.

Evanthia Roussos Torres, MD, PhD, discusses the follow-up research related to the phase 1 study of entinostat administered in combination with nivolumab and ipilimumab for the treatment of locally advanced, metastatic, unresectable, or HER2-negative breast cancer.